HRH2
Histamine H2 receptor
As of the edition of 20 October 2026, HRH2 (histamine H2 receptor, UniProt P25021) has 12 drugs tested at it and 21 companies on the list, 1 on route A and 6 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P25021
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 6
- Disease areas
- Digestive system; Immune system; Cancer; Infections; Lungs and airways; Skin and connective tissue; Nervous system; Urinary and reproductive
- Registered trials of its drugs
- 159
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 9 |
| Went quiet | 2 |
| Withdrawn from market | 1 |
| Total | 12 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Famotidine | Marketed | Phase 4 | none listed |
| Ranitidine | Marketed | Phase 4 | none listed |
| Cimetidine | Marketed | Phase 4 | none listed |
| Nizatidine | Marketed | Phase 4 | none listed |
| Lafutidine | Marketed | Phase 4 | none listed |
| HZT-501 | Went quiet | Phase 3 | none listed |
| Methantheline | Marketed | Phase 1 | none listed |
| Niperotidine | Went quiet | No phase stated | none listed |
| Roxatidine | Marketed | No phase stated | none listed |
| Betazole | Marketed | No phase stated | none listed |
| Ebrotidine | Withdrawn from market | No phase stated | none listed |
| Tolazoline | Marketed | No phase stated | none listed |
12 of 12 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 1 |
| Route B | 6 |
| Engaged | 4 |
| Undetermined | 10 |
| Total on the list | 21 |
| Company | Route |
|---|---|
| Eli Lilly | Route B |
| GSK | Route B |
| ASKA Pharmaceutical | Route B |
The other 18 companies at HRH2
In the product21 companies in all; 18 are not named here, and no score is.
See the 21 companies at HRH2, ranked, with the facts behind eachRequest access. Nothing is shown until you do.